Marek Hus
Impact in
- Hematology top 2%
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Genetics top 5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
Papers in
- Hematology 62
- Multiple Myeloma Research and Treatments 49
- Chronic Myeloid Leukemia Treatments 6
-
- Protein Degradation and Inhibitors 16
- Co-authors
- Norbert Grząśko (13 shared papers)Anna Dmoszyńska (20 shared papers)Marta Morawska (7 shared papers)Sylwia Chocholska (24 shared papers)Maria Soroka‐Wojtaszko (10 shared papers)Agnieszka Szymczyk (17 shared papers)Grzegorz Helbig (9 shared papers)Wojciech Legieć (5 shared papers)
- Journals
- Blood (10 papers)Journal of Clinical Oncology (10 papers)Oncotarget (4 papers)British Journal of Haematology (3 papers)Hematological Oncology (3 papers)
- Partner nations
- PolandUnited StatesSpain
In The Last Decade
Marek Hus
97 papers receiving 890 citations
Peers
Comparison fields: 5 of 79
- Hematology 426
- Genetics 221
- Oncology 269
- Rheumatology 88
- Cancer Research 78
Countries citing papers authored by Marek Hus
This map shows the geographic impact of Marek Hus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marek Hus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marek Hus more than expected).
Fields of papers citing papers by Marek Hus
This network shows the impact of papers produced by Marek Hus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marek Hus. The network helps show where Marek Hus may publish in the future.
Co-authors
The 25 scholars most cited alongside Marek Hus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 112 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Thalidomide treatment of resistant or relapsed multiple myeloma patients. | 2001 | 79 |
| 2 | 2014 | 62 | |
| 3 | 2011 | 49 | |
| 4 | 2016 | 45 | |
| 5 | 2022 | 42 | |
| 6 | 2012 | 39 | |
| 7 | 2002 | 30 | |
| 8 | 2017 | 30 | |
| 9 | 2023 | 29 | |
| 10 | 2019 | 25 | |
| 11 | 2011 | 25 | |
| 12 | 2014 | 23 | |
| 13 | 2019 | 23 | |
| 14 | 2022 | 19 | |
| 15 | 2020 | 19 | |
| 16 | 2009 | 18 | |
| 17 | 2020 | 16 | |
| 18 | 2013 | 15 | |
| 19 | 2024 | 14 | |
| 20 | 2017 | 14 |
About Marek Hus
Marek Hus is a scholar working on Hematology, Molecular Biology, Genetics, Oncology and Immunology, having authored 112 papers that have together received 902 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (49 papers), Chronic Lymphocytic Leukemia Research (22 papers), Protein Degradation and Inhibitors (16 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers), Eosinophilic Disorders and Syndromes (7 papers), Lymphoma Diagnosis and Treatment (7 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Cancer Treatment and Pharmacology (6 papers). The work is most often cited by research in Hematology (426 citations), Genetics (221 citations), Oncology (269 citations), Rheumatology (88 citations) and Cancer Research (78 citations). Marek Hus has collaborated with scholars based in Poland, United States and Spain. Frequent co-authors include Norbert Grząśko, Anna Dmoszyńska, Marta Morawska, Sylwia Chocholska, Maria Soroka‐Wojtaszko, Agnieszka Szymczyk, Grzegorz Helbig, Wojciech Legieć, Monika Podhorecka and Michał Szczyrek. Their work appears in journals such as Blood, Journal of Clinical Oncology, Oncotarget, British Journal of Haematology and Hematological Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.